Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Convertible Debt: 2016-2021

Historic Convertible Debt for Rocket Pharmaceuticals (RCKT) over the last 4 years, with Mar 2021 value amounting to $35.5 million.

  • Rocket Pharmaceuticals' Convertible Debt fell 22.38% to $35.5 million in Q1 2021 from the same period last year, while for Mar 2021 it was $35.5 million, marking a year-over-year decrease of 22.38%. This contributed to the annual value of $35.1 million for FY2020, which is 22.16% down from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Convertible Debt of $35.5 million as of Q1 2021, which was up 1.36% from $35.1 million recorded in Q4 2020.
  • Over the past 5 years, Rocket Pharmaceuticals' Convertible Debt peaked at $49.4 million during Q3 2017, and registered a low of $35.1 million during Q4 2020.
  • Over the past 3 years, Rocket Pharmaceuticals' median Convertible Debt value was $43.2 million (recorded in 2019), while the average stood at $42.2 million.
  • Per our database at Business Quant, Rocket Pharmaceuticals' Convertible Debt increased by 8.69% in 2019 and then decreased by 22.38% in 2021.
  • Quarterly analysis of 5 years shows Rocket Pharmaceuticals' Convertible Debt stood at $49.4 million in 2017, then declined by 17.74% to $41.4 million in 2018, then climbed by 8.69% to $45.0 million in 2019, then dropped by 22.16% to $35.1 million in 2020, then decreased by 22.38% to $35.5 million in 2021.
  • Its last three reported values are $35.5 million in Q1 2021, $35.1 million for Q4 2020, and $42.1 million during Q3 2020.